0001711754 false 0001711754 2022-12-08 2022-12-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares





Washington, D.C. 20549






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): December 8, 2022


(Exact name of registrant as specified in charter)


Nevada   001-38793   47-5205835
(State or other jurisdiction   (Commission File Number)   (IRS Employer
of incorporation)       Identification No.)


225 NE Mizner Boulevard, Suite 640, Boca Raton, FL 33432

(Address of Principal Executive Offices) (Zip Code)



(Registrant’s Telephone Number, Including Area Code)


Not Applicable

(Former Name or Former Address, If Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).


Emerging growth company 


If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   INMB   The NASDAQ Stock Market LLC







Item 8.01. Other Events.


On December 8, 2022, INmune Bio Inc. (the “Company”) issued a press release announcing that will present data from UK patients with MDS or AML treated with INKmune™ at the annual American Society for Hematology (ASH) Conference held in New Orleans December 10th – 13th. A copy of this press release is attached herewith as Exhibit 99.1.


Additionally, the Company is filing as Exhibit 99.2 to this Current Report on Form 8-K a slide deck that the Company intends to use in a presentation.


Item 9.01 Financial statements and Exhibits


(d) Exhibits.


99.1   Press Release dated December 8, 2022
99.2   Presentation
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: December 9, 2022 INMUNE BIO INC.
  By: /s/ David Moss
    David Moss
    Chief Financial Officer






Historical Stock Chart
From May 2023 to Jun 2023 Click Here for more INmune Bio Charts.
Historical Stock Chart
From Jun 2022 to Jun 2023 Click Here for more INmune Bio Charts.